VisionCare closes financing, makes board changes

Tuesday, January 24, 2012 12:51 PM

VisionCare Ophthalmic Technologies, a developer of advanced visual prosthetic devices, will close a Series E financing with Agate Medical Investments leading the expansion round.  Agate's managing general partner, Chanan Schneider, will join the VisionCare team as a board observer.

Allen W. Hill, VisionCare's CEO, said the financing will accelerate the commercial launch of its telescope implant for treating end-stage macular degeneration.

Schneider, managing general partner of Agate, previously was CEO of Beta-O2, a bio-device company, and managing director at Discount Capital Markets, where he led medtech and other technology investments.  

VisionCare also has added two new members to its board of directors: David Israeli, M.D., Pitango Venture Capital, and Yuval Avni, M.D., Giza Venture Capital.

Israeli joined Pitango in 2010 as a venture partner in the life sciences team, focusing on the medical device and biopharmaceuticals sectors. Previously, Israeli held positions at Medtronic and Rythmia Medical.

Avni is a partner at Giza Venture Capital, focusing on investments in life science and cleantech sectors. He is a medical practitioner with clinical experience in general and vascular surgery, and conducted clinical research in human genetics prior to entering the venture capital field.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs